SAB Biotherapeutics, Inc. 8-K

What Happened SAB Biotherapeutics, Inc. (SABS) announced in a Form 8‑K (filed May 4, 2026) that on April 28, 2026 it entered into a Master Manufacturing Services Agreement (MSA) with Emergent BioSolutions Canada Inc. Under the MSA, Emergent will perform clinical and commercial manufacturing and related services for SAB‑142 at Emergent’s Canadian facility. The agreement becomes effective April 28, 2026 and the contract term runs for five years from the date SAB‑142 receives FDA approval.

Key Details

• Parties: SAB Biotherapeutics, Inc. and Emergent BioSolutions Canada Inc.; MSA effective April 28, 2026.
• Term and minimum spend: five‑year term measured from FDA approval of SAB‑142; minimum aggregate spend after any FDA approval of $36 million.
• Exclusivity and alternatives: Emergent has the sole and exclusive right to manufacture the Product during the term; SAB BIO may develop an alternative source but may only purchase from alternatives in limited circumstances (when Emergent is unable or declines to manufacture).
• Pricing and payments: Commercial batch pricing to be set in a subsequent amendment; development services priced via individual statements of work; pricing may be adjusted annually.
• Termination and remedies: Termination for insolvency, non‑payment, material breach (30‑day cure, up to 90 days if diligently pursued), mutual agreement, or prolonged force majeure; if Emergent terminates for SAB BIO’s insolvency, non‑payment, or material breach, SAB BIO must pay an amount equal to the minimum annual aggregate spend for each remaining calendar year of the term, less saved costs.

Why It Matters This MSA secures a manufacturing partner for SAB‑142 and sets a defined minimum financial commitment ($36M post‑approval) that could affect SAB BIO’s future spending and production planning. Emergent’s exclusivity during the term means SAB BIO will rely on this contract for clinical and commercial supply unless limited exceptions apply. Key commercial pricing and batch fees remain to be finalized, so additional commercial cost details and their timing will be important to monitor for investors.